221 related articles for article (PubMed ID: 36377039)
41. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence.
Byeon S; Cho JH; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Cancer Med; 2020 Apr; 9(7):2352-2362. PubMed ID: 32027780
[TBL] [Abstract][Full Text] [Related]
42. Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment.
Zhang L; Bai L; Liu X; Liu Y; Li S; Liu J; Zhang S; Yang C; Ren X; Cheng Y
Thorac Cancer; 2020 May; 11(5):1170-1179. PubMed ID: 32134200
[TBL] [Abstract][Full Text] [Related]
43. Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumab.
Yamaguchi O; Kaira K; Shinomiya S; Mouri A; Hashimoto K; Shiono A; Miura Y; Akagami T; Imai H; Kobayashi K; Kagamu H
Thorac Cancer; 2021 Feb; 12(3):304-313. PubMed ID: 33185333
[TBL] [Abstract][Full Text] [Related]
44. Outcomes of Patients With Interstitial Lung Disease Receiving Programmed Cell Death 1 Inhibitors: A Retrospective Case Series.
Dobre IA; Frank AJ; D'Silva KM; Christiani DC; Okin D; Sharma A; Montesi SB
Clin Lung Cancer; 2021 Sep; 22(5):e738-e744. PubMed ID: 33663958
[TBL] [Abstract][Full Text] [Related]
45. Drug-induced interstitial lung disease after chemoimmunotherapy for extensive-stage small cell lung cancer.
Fukuda K; Katsurada N; Kawa Y; Satouchi M; Kaneshiro K; Matsumoto M; Takamiya R; Hatakeyama Y; Dokuni R; Matsumura K; Katsurada M; Nakata K; Yoshimura S; Tachihara M
Heliyon; 2023 Oct; 9(10):e20463. PubMed ID: 37822623
[TBL] [Abstract][Full Text] [Related]
46. Prevalence, Risk Factors, and Outcomes of Adult Interstitial Lung Abnormalities: A Systematic Review and Meta-Analysis.
Grant-Orser A; Min B; Elmrayed S; Podolanczuk AJ; Johannson KA
Am J Respir Crit Care Med; 2023 Sep; 208(6):695-708. PubMed ID: 37534937
[No Abstract] [Full Text] [Related]
47. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
Cho JY; Kim J; Lee JS; Kim YJ; Kim SH; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
Lung Cancer; 2018 Nov; 125():150-156. PubMed ID: 30429014
[TBL] [Abstract][Full Text] [Related]
48. Predictive Value of Interstitial Lung Abnormalities for Postoperative Pulmonary Complications in Elderly Patients with Early-stage Lung Cancer.
Jeong WG; Kim YH; Lee JE; Oh IJ; Song SY; Chae KJ; Park HM
Cancer Res Treat; 2022 Jul; 54(3):744-752. PubMed ID: 34583454
[TBL] [Abstract][Full Text] [Related]
49. Anti-PD-1-Related Exacerbation of Interstitial Lung Disease in a Patient with Non-Small Cell Lung Cancer: A Case Presentation and Review of the Literature.
L Gemmill JA; Sher A
Cancer Invest; 2020 Jul; 38(6):365-371. PubMed ID: 32559143
[TBL] [Abstract][Full Text] [Related]
50. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer.
Masuda T; Hirano C; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Ohshimo S; Fujitaka K; Hamada H; Hattori N
Cancer Chemother Pharmacol; 2018 Jan; 81(1):131-139. PubMed ID: 29143072
[TBL] [Abstract][Full Text] [Related]
51. Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
Chen X; Sheikh K; Nakajima E; Lin CT; Lee J; Hu C; Hales RK; Forde PM; Naidoo J; Voong KR
Oncologist; 2021 Oct; 26(10):e1822-e1832. PubMed ID: 34251728
[TBL] [Abstract][Full Text] [Related]
52. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
Moda M; Saito H; Kato T; Usui R; Kondo T; Nakahara Y; Murakami S; Yamamoto K; Yamada K
Thorac Cancer; 2020 Dec; 11(12):3576-3584. PubMed ID: 33078531
[TBL] [Abstract][Full Text] [Related]
53. Prevalence and prognostic meaning of interstitial lung abnormalities in remote CT scans of patients with interstitial lung disease treated with antifibrotic therapy.
García Mullor MM; Arenas-Jiménez JJ; Ureña Vacas A; Gayá García-Manso I; Pérez Pérez JL; Serra Serra N; García Sevila R
Radiologia (Engl Ed); 2024 Apr; 66 Suppl 1():S10-S23. PubMed ID: 38642956
[TBL] [Abstract][Full Text] [Related]
54. Successful treatment of a patient with non-small cell lung cancer and interstitial lung disease with durvalumab: a case report.
Tao H; Li F; Li R; Han X; Hu Y
Ann Palliat Med; 2020 Sep; 9(5):3623-3628. PubMed ID: 32648466
[TBL] [Abstract][Full Text] [Related]
55. Reticulation Is a Risk Factor of Progressive Subpleural Nonfibrotic Interstitial Lung Abnormalities.
Zhang Y; Wan H; Richeldi L; Zhu M; Huang Y; Xiong X; Liao J; Zhu W; Mao L; Xu L; Ye D; Chen L; Liu J; Fu L; Li L; Lan L; Li P; Wang L; Tang X; Luo F
Am J Respir Crit Care Med; 2022 Jul; 206(2):178-185. PubMed ID: 35426779
[No Abstract] [Full Text] [Related]
56. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
[TBL] [Abstract][Full Text] [Related]
57. Detection and Early Referral of Patients With Interstitial Lung Abnormalities: An Expert Survey Initiative.
Hunninghake GM; Goldin JG; Kadoch MA; Kropski JA; Rosas IO; Wells AU; Yadav R; Lazarus HM; Abtin FG; Corte TJ; de Andrade JA; Johannson KA; Kolb MR; Lynch DA; Oldham JM; Spagnolo P; Strek ME; Tomassetti S; Washko GR; White ES;
Chest; 2022 Feb; 161(2):470-482. PubMed ID: 34197782
[TBL] [Abstract][Full Text] [Related]
58. T cell immunity in interstitial lung disease with non-small cell lung cancer patients.
Isono T; Iwahori K; Yanagawa M; Yamamoto Y; Tone M; Haruna M; Hirata M; Fukui E; Kimura T; Kanou T; Ose N; Funaki S; Takeda Y; Morii E; Kumanogoh A; Shintani Y; Wada H
Lung Cancer; 2023 Aug; 182():107278. PubMed ID: 37321075
[TBL] [Abstract][Full Text] [Related]
59. Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies-pharmacovigilance database analysis with real-world data validation.
Guo XJ; Cai XT; Rong ZX; Zhang YP; Wen YX; Bai X; Wang J; Fu QJ; Guo ZQ; Long LL; Ma SC; Tang XR; Liu L; Guan J; Dong ZY; Wu DH
BMC Med; 2023 Jan; 21(1):6. PubMed ID: 36600276
[TBL] [Abstract][Full Text] [Related]
60. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
